C$
0.28
May 31
Business Description
NexgenRx Inc
NAICS : 621610
SIC : 8639
ISIN : CA65337X1042
Description
Financial Strength
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 3.04 | |||||
Equity-to-Asset | 0.28 | |||||
Debt-to-Equity | 0.05 | |||||
Debt-to-EBITDA | 0.35 | |||||
Interest Coverage | 4.24 | |||||
Piotroski F-Score | 7/9 | |||||
Altman Z-Score | 1.08 | |||||
Beneish M-Score | -2.32 | |||||
WACC vs ROIC |
Growth Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 9.6 | |||||
3-Year EBITDA Growth Rate | -27.9 | |||||
3-Year FCF Growth Rate | -10.6 | |||||
3-Year Book Growth Rate | 14.7 |
Momentum Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 77.22 | |||||
9-Day RSI | 78.2 | |||||
14-Day RSI | 75.4 | |||||
6-1 Month Momentum % | -12 | |||||
12-1 Month Momentum % | -31.25 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.1 | |||||
Quick Ratio | 1.1 | |||||
Cash Ratio | 0.07 | |||||
Days Sales Outstanding | 18.63 | |||||
Days Payable | 107.97 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Dividend Yield % | 3.51 | |||||
Forward Dividend Yield % | 3.51 | |||||
5-Year Yield-on-Cost % | 3.51 | |||||
3-Year Average Share Buyback Ratio | -0.3 | |||||
Shareholder Yield % | 3.3 |
Profitability Rank
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 78.18 | |||||
Operating Margin % | 0.84 | |||||
Net Margin % | 0.31 | |||||
FCF Margin % | 6.38 | |||||
ROE % | 0.53 | |||||
ROA % | 0.15 | |||||
ROIC % | 0.77 | |||||
ROC (Joel Greenblatt) % | -0.88 | |||||
ROCE % | -0.11 | |||||
Years of Profitability over Past 10-Year | 3 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | N/A | |||||
PE Ratio without NRI | N/A | |||||
Shiller PE Ratio | 38.7 | |||||
Price-to-Owner-Earnings | 40.71 | |||||
PS Ratio | 1.35 | |||||
PB Ratio | 3.06 | |||||
Price-to-Tangible-Book | 8.14 | |||||
Price-to-Free-Cash-Flow | 20.36 | |||||
Price-to-Operating-Cash-Flow | 15 | |||||
EV-to-EBIT | -2094.9 | |||||
EV-to-EBITDA | 16.29 | |||||
EV-to-Revenue | 1.43 | |||||
EV-to-FCF | 22.36 | |||||
Price-to-Projected-FCF | 1.35 | |||||
Price-to-Median-PS-Value | 0.68 | |||||
Earnings Yield (Greenblatt) % | -0.05 | |||||
FCF Yield % | 4.64 | |||||
Forward Rate of Return (Yacktman) % | 23.58 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
NexgenRx Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil C$) | 14.681 | ||
EPS (TTM) (C$) | 0 | ||
Beta | 0.32 | ||
Volatility % | 41.3 | ||
14-Day RSI | 75.4 | ||
14-Day ATR (C$) | 0.005294 | ||
20-Day SMA (C$) | 0.2555 | ||
12-1 Month Momentum % | -31.25 | ||
52-Week Range (C$) | 0.175 - 0.32 | ||
Shares Outstanding (Mil) | 70.92 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 7 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
NexgenRx Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
NexgenRx Inc Stock Events
Event | Date | Price(C$) | ||
---|---|---|---|---|
No Event Data |
NexgenRx Inc Frequently Asked Questions
What is NexgenRx Inc(TSXV:NXG)'s stock price today?
When is next earnings date of NexgenRx Inc(TSXV:NXG)?
Does NexgenRx Inc(TSXV:NXG) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |